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MemoryStrokes are preceded by oxidative stress and inﬂammation, two processes linked to atherosclerosis and hyper-
tension. Statins have beenwidely employed to control atherosclerosis; however, there could be neurological im-
plications to its use—including cognitive impairment. Thus, we aimed to determine whether alpha-tocopherol is
capable of reversing the neurological side effects of statins and enhancing its anti-inﬂammatory properties. To as-
sess these effects, 15-week-old stroke-prone spontaneously hypertensive rats (SHRSPs) were divided into four
groups (n = 6, each): alpha-tocopherol (AT), lovastatin (LoV), alpha-tocopherol + lovastatin (AT + LoV), and
control (C).We administered 120 IU of alpha-tocopherol diluted in 0.1ml of coconut oil, whereas the dose of lov-
astatin was administered at a ratio of 1 mg/kg of rat body weight. The control group received 0.1 ml coconut oil.
All animals received the treatments via orogastric gavage.We assessed body weight, diuresis, food andwater in-
take, oxidative stress (malondialdehyde levels), the total cellular injury marker (lactate dehydrogenase), short-
and long-termmemory, cognition, and histopathological changes in the hippocampus. The results demonstrated
that lovastatin treatment did not negatively affect the memory of our animal model. In fact, the animals treated
with AT and LoV showed improvement inmemory and cognition. Additionally, both treatments decrease lactate
dehydrogenase and oxidative stress levels. Furthermore, our study also demonstrated hippocampal tissue pres-
ervation in the treated groups.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
In the genesis of stroke there are two important events: inﬂammato-
ry process and oxidative stress [1], presentmainly in the atherosclerosis
and hypertension pathophysiology [2]. It seems that to control these
two events would be beneﬁcial for both primary prevention and sec-
ondary prevention.io de Janeiro State (UNIRIO),
tive-Chronic Diseases, Xavier
neiro City, Rio de Janeiro State,Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-Co-A) reductase, an enzyme responsible for inhibiting cholester-
ol biosynthesis, and is in wide use today [3]. Besides having a lipid-
lowering effect, a statin is associated with a reduction in all causes of
death from non-obstructive coronary artery disease [4]. Additionally,
some authors have found it to have a positive effect on vascular in-
ﬂammation [5], and linked it to a lower risk of developing venous
thromboembolism [6].
However, the literature indicates that there are a number of side ef-
fects, with neurological implications that include cognitive impairment
[7]. Recent studies report that statinsmay potentially cause such disease
of the nervous system as intracerebral hemorrhage [8].
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min E levels. According to Jula et al. [9], a decrease in plasma vitamin
E concentrations was noted upon treatment with statins.
Interestingly, Murad et al. [10] found improved cognitive capacity
and preserved short- and long-term memory and neuronal tissue in
stroke-prone spontaneously hypertensive rats treated with alpha-
tocopherol. Furthermore, a different study reported an association be-
tween increases in serum vitamin E levels and lower risk of cognitive
impairment [11].
Alpha-tocopherol, a powerful antioxidant, is the most potent com-
pound in the antioxidant vitamin E family and the predominant form
of vitamin E in vitamin supplements [12]. This vitamin exhibits several
inﬂuences on physiologic parameters [13,14], that could preserve neu-
ronal tissue and enhance cognitive functions.
Therefore, this study aimed to investigatewhether alpha-tocopherol
is able to reverse the statin neurological side effects and potentiates its
anti-inﬂammatory action.2. Material and methods
2.1. Animals
Twenty-four (24) male, 15-week-old SHRSPs (stroke-prone sponta-
neously hypertensive rats) weighing 180–230 g, housed in metabolic
cages in a bioterium at the Federal University of the State of Rio de
Janeiro (UNIRIO), were kept under controlled environmental condi-
tions: temperature of 21± 2 °C, light cycle kept dark for 12 h with arti-
ﬁcial light from 7:00 am–7:00 pm, humidity of 60 ± 10%, and air ﬂow
cycle of 15 min/h. All the animals were given ad libitum Nuvilab (from
Nuvital Co.) rat-food pellets and water. All procedures were carried
out in accordancewith the protocol in the conventional guide for animal
experimentation (Publication No.85-23, NIH, revised 1996) and
European Convention for the Protection of Vertebrate Animals used
for Experimental and other Scientiﬁc Purposes (Council of Europe
No. 123, Strasbourg 1985). The Ethics Committee for Animal Experi-
mentation at the Federal University of Rio de Janeiro State approved
the laboratory trials used in this study.2.2. Reagents
For the laboratory assays we used DL-alpha-tocopherol acetate
(Sigma-Aldrich, T-3376, St. Louis, MO), lovastatin (Sigma-Aldrich,
M-2147, St. Louis, MO), coconut oil (Sigma® C-1758, St. Louis, MO),
thiopental sodium (Abbott Laboratories, Abbott Park, IL), and 2-
thiobarbituric acid (Sigma-Aldrich, T-5500, St. Louis, MO).2.3. Treatment
The animals were kept under basal conditions for ten days. Thereaf-
ter, the animals were divided into four groups (n = 6, each): alpha-
tocopherol (AT), treated with 120 IU alpha-tocopherol diluted in
0.1 ml of coconut oil; lovastatin (LoV), treated with 1 mg/kg body
weight of lovastatin; alpha-tocopherol+ lovastatin (AT+ LoV), treated
with 120 IU alpha-tocopherol diluted in 0.1ml of coconut oil + 1mg/kg
bodyweight of lovastatin; and control group that only received 0.1ml of
coconut oil (C). The treatment was administered by orogastric gavage,
daily, with a polyethylene catheter PE 190 for a period of four weeks.2.4. Physiological parameters
Both groups were observed daily to note food and water intake, di-
uresis, body weight and physical aspects (skin, mucosa and hair), pos-
ture and behavior [15].2.5. Memory and cognition tests
2.5.1. Maze test
The maze test was applied to assess neurological cognition and the
ability to store memories using a cognitive map [16]. For this test, the
animals were placed in a maze measuring 30 × 55 × 55cm, and the
time it took them to complete the entire course was noted.
2.5.2. Morris Water Maze
TheMorrisWater Mazemeasured 1.8 m in diameter and was 60 cm
deep. Before ﬁlling it withwaterwe added an escape platform afﬁxed in
a permanent location in themaze. Next we ﬁlled the apparatus halfway
with water plus milk powder, to a depth of 30 cm. Thus, the hidden
platform remained a few millimeters below the surface of the water.
SHRSPs were placed in the Morris Water Maze, and when released,
the animals swam around the pool in search of an escape (hidden plat-
form). The time it took the animals toﬁnd the platformwasmeasured in
seconds. The test was conducted twice daily for each rat.
2.5.3. Novel Object Recognition Test
Initially, each SHRSP was placed in a plastic box and introduced to
two differently-shaped objects to explore freely for 5 min. This proce-
durewas repeated after 180min. Additionally, 180min after the last ex-
ercise, one of the objects was replaced by a new object with a different
shape. We thus studied the time that the rat spent with the new object
and with the familiar object. Each test lasted 10 min. In this step we
studied the preservation of short-term memory.
To assess the preservation of long-term memory, 24 h after the last
test, the novel object from the previous day was replaced by another.
The time spent with this novel object and the familiar object also was
recorded. These tests lasted 10 min.
For the short- and long-term-memory procedures, exploration was
deﬁned as snifﬁng or touching the object with the nose or front leg.
When an animal ﬁnished the test and another was to be introduced,
the objects were cleaned with alcohol and dried with paper towels, to
prevent a bias in the results due to olfactory perception. These tests
were applied during the basal period and twice a week over the course
of the entire experiment.
2.6. Sacriﬁce and blood collection
Once the experiment was complete, deep coma was induced in all
the rats by administering barbiturates (thiopental sodium) intraperito-
neally (25mg/kg). Then, we used the cervical-sterno-laparotomy surgi-
cal approach to openwide the thoracic and abdominal cavities.We then
collected blood via cardiac puncture and placed it in tubes for centrifu-
gation at 2000 ×g for 10 min in order to obtain the serum.
2.7. Brain resection
After taking the blood, we injected 0.9% NaCl saline solution into the
left ventricle of the heart towash the brain. Subsequently, extravasation
was performed by ﬂushing saline solution through a slice in the abdom-
inal aorta.
The euthanized animals were pinned in prone position and a deep
horizontal incision was made into the dorso-cervical region. A vertical
incision was made in order to expose the skullcap. The skullcap was
then fragmented to access the brain. Once accessed, we used a smooth
pinch and leveraged the brain. The attached nerves were sectioned to
complete the removal. The removed brains were then placed in a 10%
formaldehyde solution for impregnation and subsequent storage.
2.8. Malondialdehyde (MDA) levels
To assess oxidative stress, we analyzed malondialdehyde levels,
which is a lipid peroxidation marker. We performed this test using the
Fig. 3. Results of time response (s) on maze test (n= 24). *p b 0.05 considered signiﬁcant
when compared to the control group.
Fig. 1. Comparison of the MDA levels between groups (n= 24). *p b 0.05 considered sig-
niﬁcant when compared to the control group. #p b 0.05 considered signiﬁcant when com-
pared to the lovastatin group.
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tometer Micronal, model B442 (São Paulo, SP, Brazil) was used to ana-
lyze the colorimetry results and calculate the concentration of MDA
from the absorption of light at the 532-nm wavelength. The values
were expressed in nmol/ml.
2.9. Total cellular injury marker
Total lactate dehydrogenasewas determined by using the enzymatic
assay method described by Bergmeyer [17]. The values were expressed
in U/l.
2.10. Brain histopathologic analysis
The brains conserved in 10% formaldehyde solution were cleaved
and embedded in parafﬁn for processing for microscopic analysis. The
parafﬁn block was cut to a thickness of 5 μmusing a Gung RM 2025mi-
crotome (Leica, Nussloch, Germany) and stained with hematoxylin and
eosin (H&E). Signs of injury to the hippocampal region were identiﬁed
using an optical microscope (Olympus Optical BX-40, Tokyo, Japan)
with a magniﬁcation range of 40× to 400×. The total numbers of cells
in the hippocampus and in the CA1, CA2 and CA3 subregions were
counted. The slides were prepared in cross-sections, and quantiﬁcationFig. 2. Comparison of the LDH levels between groups (n = 24). *p b 0.05 considered sig-
niﬁcant when compared to the control group.was performed via microscopic observation of 40 ﬁelds per slide at high
magniﬁcation (200×).2.11. Statistical analysis
The results were expressed in mean ± standard deviation and sub-
sequently analyzed using the one-way ANOVA test with Tukey's post
hoc test. The statistical software package used was GraphPad Prism®
5.0 for Windows® (Graph Pad Software, San Diego, CA, USA).
To assess the ability to recognize novel objects in the Novel Object
Recognition Test, a discrimination index (DI) provided the new-
object-exploration-to-recognition time ratio. This index was deter-
mined using the following formula: Mean novel object-exploration
time/(sum of mean total exploration time [mean novel object-explora-
tion time + mean familiar object-exploration time]) × 100. For these
data, we also applied the one-way ANOVA test and Tukey's post hoc
test. The value p b 0.05 was considered statistically signiﬁcant.3. Results
3.1. Lovastatin associated with alpha-tocopherol signiﬁcantly reduces LDH
levels
Despite evidence suggesting that it has a protective effect on cells, the
lovastatin group did not show a signiﬁcant decrease in lactate dehydro-
genase levels. On the other hand, the association of lovastatin + alpha-
tocopherol did lead to a signiﬁcant decrease in themarker. Furthermore,
the alpha-tocopherol group also had decreased the LDH levels. These re-
sults show that alpha-tocopherol may be capable of modulating LDH
levels. The control group presented increased values of lactate dehydro-
genase (Fig. 1).Fig. 4. Results of time response (s) onMorrisWater Maze test (n = 24). *p b 0.05 consid-
ered signiﬁcant when compared to the control group.
Fig. 7.Countingof the total cell number in the hippocampus (n=24). *pb 0.05 considered
signiﬁcant when compared to the control group.
Fig. 5. Discrimination index of Novel Object Recognition Test: Short-term memory
(n = 24).
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ministered alone reduces more efﬁciently thiobarbituric acid-reactive
substances
Surprisingly, lovastatin treatmentwas shown tohave a signiﬁcant an-
tioxidant effect and promote a signiﬁcant decrease in malondialdehyde
(MDA) levels. However, this product of lipid peroxidation was signiﬁ-
cantly lower in the alpha-tocopherol group (p b 0.05). The alpha-
tocopherol + lovastatin group also showed a signiﬁcant decrease in
MDA, though this data was not signiﬁcant when compared to the lova-
statin group (p N 0.05) (Fig. 2).3.3. Alpha-tocopherol and lovastatin preserve memory and cognitive
function
The results from themaze test showed a signiﬁcant difference in the
runtimes of the lovastatin and alpha-tocopherol groups when com-
pared to the control group. Firstly, on week two the alpha-tocopherol
group showed a signiﬁcant decrease in the time that it took to complete
the task. From the third week, the lovastatin and alpha-tocopherol +
lovastatin groups lowered the time that it took them to complete the
task. There was no signiﬁcant difference between the alpha-tocopherol,
alpha-tocopherol + lovastatin and lovastatin groups (Fig. 3).3.4. Alpha-tocopherol and lovastatin improve spatial memory in SHRSPs
The results from the Morris Water Maze test were similar to those
from the maze test. The data indicates that there was a signiﬁcant de-
crease in escape latency in the groups treated with lovastatin and
alpha-tocopherol. These results may suggest that spatial memory for-
mation is preserved and improved in the SHRSPs treatedwith lovastatin
and alpha-tocopherol (Fig. 4).Fig. 6. Discrimination index of Novel Object Recognition Test: Long-term memory
(n = 24).3.5. Treatment with alpha-tocopherol and lovastatin enhances the discrim-
ination index in the Novel Object Recognition Test
The control group showed a reduced discrimination index, which
could indicate cognitive impairment. Treatment with lovastatin or
alpha-tocopherol prompted an improvement in the discrimination
index when compared to the control group. These results seem to indi-
cate that treatment with either alpha-tocopherol or lovastatin, or with a
combination of these two substances, makes a signiﬁcant contribution
to the preservation of memory (Fig. 5 and Fig. 6).3.6. The hippocampus can be preserved in SHRSPs treated with lovastatin
and alpha-tocopherol
Regarding histopathological evaluation, examination of the hippo-
campus revealed that the total number of cells in the hippocampus
was signiﬁcantly higher in the rats treated with lovastatin or alpha-
tocopherol (Fig. 7). The CA1, CA2 and CA3 subregions of the hippocam-
puswere also examined, and the cell counts conﬁrm these ﬁndings (Fig.
8). These data do indeed suggest preservation of the neuronal tissue and
consequently possible enhancement of memory and cognition.
Additionally, some neuronal injuries were found in the control
group. In the hippocampus of this group, glial nodules and vessel prolif-
eration were detected. In contrast, the hippocampus tissue of the
SHRSPs treated with alpha-tocopherol, lovastatin or alpha-tocopherol +
lovastatin did not show any such changes (Fig. 9). These ﬁndings may
corroborate the impairment of cognitive and memory functions foundFig. 8. Counting of the hippocampus CA1, CA2 and CA3 subregions. *p b 0.05 considered
signiﬁcant when compared to the control group.
Fig. 9. Histopathological injuries observed in cross sections of the hippocampus. (A) Control group. Presence of glial nodules (1) and proliferative vessels (2) (H&E, ×40). (B) Lovastatin
group (H&E, ×40). (C) Alpha-tocopherol group (H&E, ×400). (D) Alpha-tocopherol + lovastatin (H&E, ×400).
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groups receiving treatment.3.7. Alpha-tocopherol and lovastatin did not change physiological
parameters
All the SHRSPs showed ﬂuctuations in body weight during the four
weeks of treatment, however, with no statistical signiﬁcance. Neither
did the assessment of diuresis andwater and food intake identify signif-
icant changes between the groups at any point during the four-week ex-
periment (Table 1). Physical examination of the animals did not reveal
any changes that would indicate any adverse effect resulting from the
treatment.Table 1
Results of biological parameter measurement (n = 24).
Parameters Groups Basal period 1st week
Body weight (g) Control
AT
Lovastatin
AT + lovastatin
197.33 ± 13.74
200 ± 9.74
196.69 ± 10.13
198.81 ± 11.71
201.23 ±
203 ± 14
205.61 ±
202.21 ±
Diuresis (ml) Control
AT
Lovastatin
AT + lovastatin
6.87 ± 3.43
7.56 ± 2.03
6.43 ± 0.63
6.19 ± 2.65
5.63 ± 2
5.26 ± 3
5.71 ± 1
6.63 ± 1
Food intake (g) Control
AT
Lovastatin
AT + lovastatin
14.56 ± 2.32
14 ± 1.46
14.85 ± 2.45
15.17 ± 2.52
15.47 ±
17.45 ±
16.29 ±
17.82 ±
Water intake (ml) Control
AT
Lovastatin
AT + lovastatin
45.98 ± 3.46
47.74 ± 8.87
41.78 ± 4.22
41.97 ± 5.19
49.69 ±
46.95 ±
35.15 ±
32.32 ±
The values represent the mean ± SD of 24 animals.
AT: alpha-tocopherol.4. Discussion
Despite studies reporting neurological impairment due to the use of
statin, the present article demonstrates that treatment with lovastatin
promotes the preservation of memory and cognition. These results cor-
roborate the ﬁndings of Mans et al. [18], who demonstrated that acute
treatment using simvastatin for 2 to 4 h in C57BL/6mice signiﬁcantly in-
creases the magnitude of long-term potentiation (LTP) of synapses in
the hippocampal CA1 and CA3 ﬁelds. The authors also showed that
phosphorylation of protein kinase B increased signiﬁcantly in the CA1
region after treatment and that inhibition of this protein suppresses
the increase in LTP induced by simvastatin. These results suggest that
activating protein kinase B can promote an increase in LTP in the hippo-
campus through statin treatment.2nd week 3rd week 4th week
16.83
.56
12.23
11.33
210.87 ± 7.84
215.69 ± 13.56
211.23 ± 14.50
210.76 ± 12.06
218 ± 10.55
220.76 ± 11.27
213.45 ± 11.67
211.79 ± 12.96
216.97 ± 9.86
215.67 ± 11.56
212.35 ± 12.48
211.88 ± 13.73
.03
.03
.47
.75
6.54 ± 2.33
5.38 ± 2.03
6.81 ± 0.91
6.52 ± 1.73
6.45 ± 2.33
6.23 ± 1.55
7.12 ± 3.11
6.73 ± 0.69
7.83 ± 1.23
6.87 ± 0.92
6.98 ± 2.56
6.41 ± 0.81
1.34
1.21
2.84
2.15
15.99 ± 0.87
15.88 ± 1.60
12.41 ± 2.98
14.82 ± 1.45
13.57 ± 2.07
16.95 ± 3.05
12.19 ± 3.33
13.44 ± 1.88
14.56 ± 3.36
13.48 ± 3.81
10.92 ± 1.26
12.31 ± 2.24
4.76
6.78
2.19
6.31
37 ± 6.68
40.31 ± 7.43
39.51 ± 1.25
31.39 ± 7.97
32.68 ± 3.23
37.69 ± 5.41
33.32 ± 2.73
32.36 ± 2.94
38. 67 ± 5.78
34.19 ± 6.12
35.64 ± 6.97
28.93 ± 9.44
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modulating memory formation and preserving cognition. According
to Wu et al. [19], alpha-tocopherol can increase molecular factors
involved in memory consolidation, such as BDNF (brain-derived
neurotrophic factor), CREB (cAMP response element-binding) and
synapsin I. These factors may be affected by oxidative stress. Previ-
ous studies by our group demonstrated that alpha-tocopherol can
be considered a modulator for stroke-risk factors and a neuroprotec-
tive agent, promoting the preservation of neural tissue and function
[10].
Additionally, vitamin E-deﬁciency may lead to an impaired induc-
tion of LTP, which could have an inﬂuence on the memory formation
[20]. Moreover, vitamin E can modulate protein kinase B, possibly in-
creasing survival of neuronal cells [21].
Furthermore, the authors report that in the process of neuronal
injury, the levels of thiobarbituric acid, hydroperoxides and isoprostane
increased in the brain of the rats affected by oxidative stress [22].
Oxidative stress can trigger the processes of necrosis and apoptosis
[23]. These events can be determined by injury markers like LDH en-
zyme. Donnan et al. [24] reported an association between LDH levels
and stroke. Some authors also report that alpha-tocopherol has an
anti-inﬂammatory property, which could suggest a decrease in serum
LDH levels [25].
Conﬁrming this data, Tsai et al. [26] found that LDH increased after
subjecting experimental animals to medium artery occlusion. However,
in the same study when the authors treated the animals with resvera-
trol, a powerful antioxidant, there was a signiﬁcant decrease in this in-
jury marker. This could be associated with the antioxidant effect of
resveratrol.
Reactive oxygen species can react with biological structures (e.g.,
plasmatic membranes), and generate measurable products. In the con-
trol group, LDH and malondialdehyde levels were higher than in the
other groups, and only the control group was found to have hippocam-
pal injury. This tissue injurymay have been responsible for the impaired
cognition and memory. Indeed, Watson et al. have reported that lipid
peroxidation may be involved in the progressive decline in memory
and learning performance [27].
On the other hand, rats treated with lovastatin or alpha-tocopherol
showed improvement in neurological functions and nohippocampal in-
jurywas noted. LDH levelswere signiﬁcantly lower in the animals of the
alpha-tocopherol group. However, lovastatin did not seem to alter
injury-marker levels. Surprisingly, we found an interesting association
between alpha-tocopherol and lovastatin, which together promoted a
major decrease in LDH levels.
We also found that lovastatin promoted a signiﬁcant decrease in
malondialdehyde levels. Other authors also have described the antioxi-
dant properties of lovastatin. Chang et al. [28] reported a decrease in
malondialdehyde levels and oxidative DNA injury in rabbits treated
with lovastatin. These data can be conﬁrmed by Kumar et al. [29], that
reported an increase in antioxidant-enzyme activity and a decrease in
thiobarbituric acid-reactive substances in liver and heart tissue from
rats treated with lovastatin.
The antioxidant activities of statins can be explained by the increase
in catalase, paraoxonase, vitamin E and eNOS levels. These events could
trigger a decrease in reactive oxygen species production and lipid per-
oxidation [30]. Additionally, Guasti et al. [31] linked the antioxidant
effect of statins with the decrease in angiotensin II type 1 receptor ex-
pression, which is responsible for endothelial dysfunction.
Nevertheless, alpha-tocopherol was the most effective treatment
for reducing the oxidative stress marker. The combination of alpha-
tocopherol and lovastatin showed a slight decrease in lipid peroxidation
levels, compared to the lovastatin group.
Recent ﬁndings demonstrate that lovastatin could prevent an in-
crease in LDH levels and have a neuroprotective effect [32]. Clinical trials
have shown improvement in the cognition of children with neuroﬁbro-
matosis treated with lovastatin [33].The antioxidant and anti-inﬂammatory effects of lovastatin and
alpha-tocopherol could be what preserved the hippocampal tissue and
increased the number of cells in the hippocampus (CA1, CA2 and CA3)
in the test groups. In turn, the control group showed a decrease in the
number of hippocampal cells, and histopathologically glial nodules
and vessel proliferation were detected. Glial nodules may be associated
with an inﬂammatory process and responsible for provoking learning
and memory impairment [34,35].
Both histological alterations found in our work could be a signal of
cerebral ischemia [36], explained by high blood pressure, which is a
characteristic of the strain of animal used [37,38]. Additionally, the an-
giogenesis (proliferation vessel) here observed has been described by
other authors. Studies report upregulation of angiogenesis gene expres-
sion a few minutes after ischemic stroke in rodents, as well as an in-
crease in angiogenic proteins in the ischemic area weeks thereafter
[39,40].
Furthermore, SHRSPs have a condition that exacerbates reactive ox-
ygen species production, causing injury to cellular integrity and playing
a part in processes that lead to the death of brain tissue [37,38].
Some studies suggest that reduced redox potential in hippocampal
neurons provokes impairment of long-term potentiation and deﬁcient
cognitive functions [41]. However, according to Emmrich et al. [41],
modulation of oxidative reactions by alpha-tocopherol could preserve
brain cell metabolism and restore cognitive functions.
5. Conclusion
In sum, the evidence from this study demonstrates that treatment
using lovastatin did not have a negative effect on cognition andmemory
nor produce any deleterious effects on ourmodel. In fact, therewas hip-
pocampal tissue preservation and we observed an improvement of the
cognition and memory functions in rats treated with lovastatin and
alpha-tocopherol.
Disclosure
The authors declare no conﬂicts of interest.
Acknowledgments
This study was supported by CNPq, CAPES and UNIRIO.
References
[1] T.H. Sanderson, C. Reynolds, R. Kumar, K. Przyklenk, M. Huttemann, Molecular
mechanism of ischemia-reperfusion injury in brain: pivotal role of themitochondri-
al membrane potential in reactive species generation, Mol. Neurobiol. 47 (2013)
9–23.
[2] F.A. McAlister, S.R. Majumdar, R.S. Padwal, M. Fradette, A. Thompson, A. Buck, et al.,
Case management for blood pressure and lipid level control after minor stroke: pre-
vention randomized controlled trial, CMAJ 186 (8) (2014) 577–584.
[3] W. Wang, B. Zhang, Statins for the prevention of stroke: a meta-analysis of random-
ized controlled trials, PLoS One 9 (3) (2014) 1–10.
[4] I.C. Hwang, J.Y. Jeon, Y. Kim, H.M. Kim, Y.E. Yoon, S.P. Lee, et al., Statin therapy is as-
sociated with lower all-cause mortality in patients with non-obstructive coronary
artery disease, Atherosclerosis 293 (2) (2015) 335–342.
[5] A. Blum, HMG-CoA reductase inhibitors (statins), inﬂammation, and endothelial
progenitor cells—new mechanistic insights of atherosclerosis, Biofactors 40 (3)
(2014) 295–302.
[6] D. Khemasuwan, Y.K. Chae, S. Gupta, A. Carpio, J.H. Yun, S. Neagu, et al., Dose-related
effect of statins in venous thrombosis risk reduction, Am. J. Med. 124 (9) (2011)
852–859.
[7] M. Tuccori, S. Montagnani, S. Mantarro, A. Capogrosso-Sansone, E. Ruggiero, A.
Saporite, et al., Neuropsychiatric adverse events associated with statins: epidemiol-
ogy, pathophysiology, prevention and management, CNS Drugs 28 (3) (2014)
249–272.
[8] Q. Lei, W.N. Peng, H. You, Z.P. Hu, W. Lu, Statins in nervous system-associated dis-
eases: angels or devils? Pharmazie 69 (6) (2014) 448–454.
[9] A. Jula, J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas, T. Ronnemaa, Effects of
diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterol-
emic men: a randomized controlled trial, J. Am. Med. Assoc. 287 (2002) 598–605.
309M.R.M. Guimarães et al. / Physiology & Behavior 149 (2015) 303–309[10] L.B. Murad,M.R. Guimarães, A. Paganelli, C.A. Basílio-de-Oliveira, L.M. Vianna, Alpha-
tocopherol in the brain tissue preservation of stroke-prone spontaneously hyper-
tensive rats, J. Physiol. Biochem. 70 (1) (2014) 49–60.
[11] F. Mangialasche, A. Solomon, I. Kareholt, B. Hooshmand, R. Cecchetti, L. Fratiglioni,
et al., Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish
cohort of older adults, Exp. Gerontol. 48 (12) (2013) 1428–1435.
[12] H.J. Kayden, M.G. Traber, Absorption, lipoprotein transport, and regulation of plasma
concentrations of vitamin E in humans, J. Lipid Res. 34 (1993) 343–358.
[13] A. Azzi, R. Ricciarelli, J.M. Zingg, Non-antioxidant molecular functions of alpha-
tocopherol (vitamin E), FEBS Lett. 519 (2002) 8–10.
[14] R. Ricciarelli, J.M. Zingg, A. Azzi, The 80th anniversary of vitamin E: beyond its anti-
oxidant properties, Biol. Chem. 383 (2002) 457–465.
[15] L.M. Vianna, Manual de Fisiologia Experimental, 1st ed. Yendis Editora, São Caetano
do Sul, 2009.
[16] S.T. Fujimoto, L. Longhi, K.E. Saatman, V. Conte, N. Stocchetti, T.K. Mcintosh, Motor
and function evaluation following experimental traumatic brain injury, Neurosci.
Biobehav. Rev. 28 (4) (2004) 365–378.
[17] H.U. Bergmeyer, Methods of Enzymatic Analysis, 3 ed. Verlag, New York, 1983.
[18] R.A. Mans, N. Chowdhury, D. Cao, L.L. McMahon, L. Li, Simvastatin enhances hippo-
campal long-potentiation in C57BL/6 mice, Neuroscience 166 (2) (2010) 435–444.
[19] A. Wu, Z. Ying, F. Gomez-Pinilla, Vitamin E protects against oxidative injury and
learning disability after mild traumatic brain injury in rats, Neurorehabil. Neural
Repair 24 (2010) 290–298.
[20] Z. Xie, B.R. Sastry, Impairment of long-term potentiation in rats fed with vitamin E-
deﬁcient diet, Brain Res. 681 (1–2) (1995) 193–196.
[21] J.M. Zingg, R. Libinaki, C.Q. Lai, M. Meydani, R. Gianello, E. Ogru, A. Azzi, Modulation
of gene expression by α-tocopherol and α-tocopheryl phosphate in THP-1 mono-
cytes, Free Radic. Biol. Med. 49 (12) (2010) 1989–2000.
[22] H. Sato, T. Takahashi, K. Sumitani, H. Takatsu, S. Urano, Glucocorticoids generates
ROS to induce oxidative injury in the hippocampus, leading to impairment of cogni-
tive function of rats, J. Clin. Biochem. Nutr. 47 (2010) 224–232.
[23] M. Tagami, K. Yamagata, K. Ikeda, Vitamin E prevents apoptosis in cortical neurons
during hypoxia and oxygen reperfusion, Lab. Investig. 78 (11) (1998) 1415–1429.
[24] G.A. Donnan, P. Zapf, A.E. Doyle, P.F. Bladin, CSF enzymes in lacunar and cortical
stroke, Stroke 14 (2) (1983) 266–269.
[25] D. Giakoustidis, G. Papageorgiou, S. Iliadis, N. Kontos, E. Kostopoulou, A.
Papachrestou, et al., Intramuscular administration of very high dose of alpha-
tocopherol protects liver from severe ischemia/reperfusion injury, World J.
Surg. 26 (7) (2002) 872–877.
[26] S. Tsai, L. Hung, Y. Fu, H. Cheng, M. Nien, H. Liu, Resveratrol neuroprotective effects
during focal cerebral ischemia injury via nitric oxidemechanism in rats, J. Vasc. Surg.
46 (2007) 346–353.
[27] S.N. Watson, T.E. Risling, P.M. Hermann, W.C. Wildering, Failure of delayed
nonsynaptic neuronal plasticity underlies age-associated long-term associative
memory impairment, BMC Neurosci. 13 (2012) 103.[28] W.C. Chang, Y.M. Yu, Y.M. Hsu, C.H. Wu, P.L. Yin, S.Y. Chiang, et al., Inhibitory effect
of Magnolia ofﬁcinalis and lovastatin on aortic oxidative stress and apoptosis in hy-
perlipidemic rabbits, J. Cardiovasc. Pharmacol. 47 (3) (2006) 463–468.
[29] S. Kumar, N. Srivastava, J. Gomes, The effect of lovastatin on oxidative stress and
antioxidante enzymes in hydrogen peroxide intoxicated rats, Food Chem. Toxicol.
49 (4) (2011) 898–902.
[30] E. Profumo, B. Buttari, L. Saso, R. Rigano, Pleiotropic effects of statins in atheroscle-
rotic disease: focus on the antioxidant activity of atorvastatin, Curr. Top. Med.
Chem. 14 (22) (2014) 2542–2551.
[31] L. Guasti, F. Marino, M. Cosentino, R.C. Maio, E. Rasini, M. Ferrari, et al., Prolonged
statin-associated reduction in neutrophil reactive oxygen species and angiotensin
II type 1 receptor expression: 1-year follow-up, Eur. Heart J. 29 (9) (2008) 1118–1126.
[32] J.Q. Yan, Y.J. Ma, J.C. Sun, S.F. Bai, L.N. Huang, Neuroprotective effect of lovastatin by
inhibiting NMDA receptor 1 in 6-hydroxydopamine treated PC12 cells, Int. J. Clin.
Exp. Med. 15 (7) (2014) 3313–3319.
[33] M.T. Acosta, P.G. Kardel, K.S.Walsh, K.N. Rosenbaum, G.A. Gioia, R.J. Packer, Lovastat-
in as treatment for neurocognitive deﬁcits in neuroﬁbromatosis type 1: phase I
study, Pediatr. Neurol. 45 (4) (2011) 241–245.
[34] Y.H. Zhou, X.B. Wang, S.F. Jiang, Y.L. Xu, J.P. Tao, X.P. Zhang, et al., Impairment of
learning and memory ability in mice with latent infection of Toxoplasma gondii,
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 29 (5) (2011)
333–338.
[35] B.B. Gelman, J.G. Lisinicchia, S. Morgello, E. Masliah, D. Commins, C.L. Achim, et al.,
Neurovirological correlation with HIV-associated neurocognitive disorders and en-
cephalitis in a HAART-era cohort, J. Acquir. Immune Deﬁc. Syndr. 15 (62 (5))
(2013) 487–495.
[36] B.J. Snider, C. Du, L. Wei, D.W. Choi, Cycloheximide reduces infarct volumewhen ad-
ministered up to 6 h after mild focal ischemia in rats, Brain Res. 917 (2001)
147–157.
[37] M.W. McBride, M.J. Brosnan, J. Mathers, L.I. McLellan, W.H. Miller, D. Graham, et al.,
Reduction of Gstm1 expression in the stroke-prone spontaneously hypertension rat
contributes to increased oxidative stress, Hypertension 45 (4) (2005) 786–792.
[38] A. Michihara, M. Sawamura, Y. Yamori, K. Akasaki, H. Tsuji, Comparison of subcellu-
lar distribution of mevalonate pyrophosphate decarboxylase between stroke-prone
spontaneously hypertensive rat and Wistar Kyoto rat, Biol. Pharm. Bull. 25 (6)
(2002) 734 -737, 2002.
[39] T. Hayashi, N. Noshita, T. Sugawara, P.H. Chan, Temporal proﬁle of angiogenesis and
expression of related genes in the brain after ischemia, J. Cereb. Blood Flow Metab.
23 (2003) 166–180.
[40] J. Krupinski, R. Issa, T. Bujny, M. Slevin, P. Kumar, S. Kumar, et al., A putative role for
platelet-derived growth factor in angiogenesis and neuroprotection after ischemic
stroke in humans, Stroke 28 (1997) 564–573.
[41] P. Emmrich, J. Hahn, V. Ogunlade, K. Geiger, R. Schober, F.W. Mohr, Neuropatholog-
ical ﬁndings after cardiac surgery—retrospective study over 6 years, Z. Kardiol. 92
(2003) 925–937.
